Changing the world

UCLB is the commercialisation company of UCL. We bring to market truly world-leading, world-changing technologies and innovations that have a real and positive impact on people’s lives.

Find out more


BioMarin Logo

First gene therapy for adults with severe Haemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), approved by European Commission (EC)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe haemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

Read more News


Gene therapy

Accelerating gene therapies by the power of four

Bloomsbury Genetic Therapies is a new UCLB biotech spinout with ambitions to go far and fast. Formally launched in October, the company is leveraging a powerful partnership of four UCL academics to develop new treatments for rare genetic diseases.

Read more case studies